Developer docs
API playgroundTry for free, no card

Search company profiles

Codex DNA

Full company profile

uuid00026ap

Namestring
Codex DNA
Legal namestring
Telesis Bio Inc.
Websiteurl
codexdna.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Codex DNA, operating commercially as Telesis Bio, is a synthetic biology company that develops automated platforms for on-site DNA and mRNA synthesis. Its core offering, the BioXp Platform, comprises benchtop (BioXp 3250) and high-throughput (BioXp 9600) synthesis systems paired with proprietary reagent kits covering mRNA synthesis, gene synthesis, DNA cloning, DNA amplification, library construction, and NGS library preparation. The Gibson SOLA Platform is an enzyme-based DNA assembly technology licensed to enterprise customers for internal rapid gene synthesis. The myBioXperience portal provides a secure cloud interface for sequence submission and order management. According to firmographic data, the company is publicly listed on NASDAQ (ticker DNAY), was founded in 2011, is headquartered in San Diego, California, and employs 101–250 people.

The company targets biotechnology and pharmaceutical customers, with named application areas in antibody drug discovery, cell and gene therapy, and vaccine development, as well as vaccine developers building mRNA candidates. Its value proposition is built on speed and control: the platform is positioned to reduce time to results by up to 90% versus traditional outsourcing and enable a 3-day sequence-to-result mRNA workflow, while retaining intellectual property and build timeline control on the customer side. Membership in the International Gene Synthesis Consortium signals compliance with biosecurity best practices relevant to gene synthesis procurement.

Telesis Bio monetizes through three streams: sale of BioXp hardware systems, recurring revenue from BioXp consumable kits tied to the installed base, and enterprise licensing of the Gibson SOLA technology. Distribution combines direct enterprise field sales, a self-service customer portal for consumables, OEM-style licensing to biopharma partners (notably Regeneron, signed May 2025), and a global distributor network. The company has historically supplemented organic growth with M&A, including the November 2021 acquisition of Eton Bioscience for $13 million, and a $25 million financing round in September 2019 led by Northpond Ventures.

Short descriptiontext

Codex DNA, operating as Telesis Bio, is a publicly traded synthetic biology company that sells automated BioXp DNA/mRNA synthesis systems, proprietary reagent kits, and Gibson SOLA enzyme-based DNA assembly technology to biotechnology and pharmaceutical customers for therapeutic discovery workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
synthetic biology automation, DNA synthesis systems, mRNA synthesis kits, gene assembly technology, biomolecule synthesis platforms
Industry3 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Automated Synthetic Biology Instrumentation
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1BioXp Systems (Hardware)
TypeHardware Sales
Description

Sale of automated BioXp synthesis systems including BioXp 3250 and BioXp 9600 platforms for on-site biomolecule synthesis.

telesisbio.com
2BioXp Kits (Consumables)
TypeSubscription Recurring
Description

Recurring sales of proprietary reagent kits for mRNA synthesis, gene synthesis, DNA cloning, DNA amplification, and NGS library preparation. Consumable revenue from repeat orders.

telesisbio.com
3Gibson SOLA Licensing
TypeLicensing Royalties
Description

Technology licensing agreements allowing partners to deploy Gibson SOLA technology for internal rapid DNA and gene synthesis capabilities.

telesisbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based enterprise pricing for BioXp systems and consumables
ModelOtherBilling cadenceMulti-year contract
Notes

No specific price points publicly disclosed. Sales team engagement required for quotation.

telesisbio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1BioXp Platform
Description

Automated platform for synthesis of DNA, mRNA, and other biomolecules

telesisbio.com
+2 more records
Core offering1 text field

Codex DNA (Telesis Bio) sells automated benchtop synthesis systems—the BioXp 3250 and 9600 platforms—alongside proprietary BioXp reagent kits for on-site DNA, mRNA, gene synthesis, DNA cloning, amplification, libraries, and NGS library preparation. It also licenses its Gibson SOLA enzymatic DNA assembly technology to biopharma enterprises for internal deployment. The offering enables biotechnology and pharmaceutical researchers to perform rapid, on-demand synthesis of biomolecules, reducing reliance on external CROs/outsourcing for therapeutic discovery workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Up to 90% time reduction compared to traditional outsourcing methods
+2 more records
Product overview1 text field

Telesis Bio (formerly operating as Codex DNA) offers a platform-plus-modules architecture centered on two core product lines: the BioXp Platform and the Gibson SOLA Platform. The BioXp Platform consists of automated synthesis systems (BioXp 3250 System and BioXp 9600 system) that work with a suite of BioXp Kits for mRNA synthesis, gene synthesis, DNA cloning, DNA amplification, libraries, and NGS library preparation. The Gibson SOLA Platform provides rapid on-site DNA and gene synthesis capabilities for integration with standard lab automation. Both platforms are supported by the myBioXperience secure ordering portal. The company focuses on therapeutic discovery applications including antibody drug discovery, cell and gene therapy, and vaccine development, enabling researchers to reduce time to results by up to 90% compared to traditional outsourcing methods.

Product and service4 records
1BioXp 3250 System
CategoryAutomated synthesis hardware
Description

A benchtop automated synthesis system within the BioXp platform for DNA and mRNA production, designed for biotech and pharmaceutical researchers who need rapid, on-site synthesis of biomolecules for therapeutic discovery.

2BioXp 9600 System
CategoryAutomated synthesis hardware
Description

A higher-throughput automated synthesis system within the BioXp platform for larger-scale DNA and mRNA production, targeting enterprise biotech and pharmaceutical customers with greater volume requirements for therapeutic discovery workflows.

3BioXp Kits
CategoryConsumable reagent kits
Description

Proprietary consumable reagent kits designed for use on BioXp systems, covering mRNA synthesis, gene synthesis, DNA cloning, DNA amplification, library creation, and NGS library preparation. Sold as a recurring consumable line to researchers running BioXp workflows.

4Gibson SOLA Platform
CategoryLicensed synthetic biology technology
Description

Enzyme-based DNA assembly technology that enables rapid, high-fidelity on-site gene synthesis and cloning, designed to integrate with standard lab automation. Licensed to biopharma enterprises such as Regeneron to provide internal rapid DNA and gene synthesis capabilities for therapeutic discovery.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-05-28
Description

Regeneron has licensed the Gibson SOLA platform to enable rapid on-site DNA and gene synthesis capabilities for powering their therapeutic discovery pipeline. This licensing agreement represents a flagship enterprise customer adoption of the technology for internal deployment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Directly competes with Telesis Bio in synthetic DNA and gene synthesis, serving biotech and pharma with high-throughput synthesis platforms and oligo products. Highly overlapping customer base in antibody discovery and therapeutic R&D.

2DNA Script
TypeDirect peer
Description

Competes in enzymatic on-site DNA synthesis with the SYNTAX benchtop platform, directly addressing the same 'on-site, IP-controlled synthesis' pain point that Gibson SOLA targets.

TypeBroad incumbent
Description

Large incumbent offering gene synthesis services and products to biotech and pharma customers. Overlaps with Telesis Bio's gene synthesis and mRNA workflow offerings, though primarily via outsourced service model.

TypeBroad incumbent
Description

Danaher-owned leader in oligonucleotide and gene synthesis, serving the same biotech/pharma customer base with synthetic nucleic acid products. Represents an entrenched incumbent in molecular biology consumables.

TypeDirect peer
Description

Provides synthetic biology tools including engineered cells and gene synthesis services to therapeutic developers, overlapping with Telesis Bio's customer segments in cell/gene therapy and drug discovery.

TypeEmerging player
Description

Pioneer in enzymatic DNA synthesis with a benchtop synthesis platform aimed at displacing outsourced gene synthesis. Direct technology competitor to Gibson SOLA's enzymatic synthesis approach.

TypeBroad incumbent
Description

Major provider of outsourced gene synthesis and molecular biology services globally. Competes for the same biotech/pharma workflow budgets that Telesis Bio aims to internalize via the BioXp platform.

TypeBroad incumbent
Description

Diversified life sciences tools giant offering instruments, reagents, and services across molecular biology and synthetic biology. Competes indirectly via broader portfolio including gene synthesis and nucleic acid workflow tools.

TypeBroad incumbent
Description

Major analytical instrument and genomics consumables provider. Overlaps with Telesis Bio in molecular biology instrumentation and oligo/NGS consumables serving biotech and pharma R&D.

TypeEmerging player
Description

Synthetic biology tools company offering gene synthesis and protein engineering services, with overlapping customer base in antibody discovery and therapeutic protein development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Codex DNA

Automated Synthetic Biology Instrumentationcodexdna.com

Codex DNA, operating as Telesis Bio, is a publicly traded synthetic biology company that sells automated BioXp DNA/mRNA synthesis systems, proprietary reagent kits, and Gibson SOLA enzyme-based DNA assembly technology to biotechnology and pharmaceutical customers for therapeutic discovery workflows.

What Codex DNA does

Codex DNA, operating commercially as Telesis Bio, is a synthetic biology company that develops automated platforms for on-site DNA and mRNA synthesis. Its core offering, the BioXp Platform, comprises benchtop (BioXp 3250) and high-throughput (BioXp 9600) synthesis systems paired with proprietary reagent kits covering mRNA synthesis, gene synthesis, DNA cloning, DNA amplification, library construction, and NGS library preparation. The Gibson SOLA Platform is an enzyme-based DNA assembly technology licensed to enterprise customers for internal rapid gene synthesis. The myBioXperience portal provides a secure cloud interface for sequence submission and order management. According to firmographic data, the company is publicly listed on NASDAQ (ticker DNAY), was founded in 2011, is headquartered in San Diego, California, and employs 101–250 people.

The company targets biotechnology and pharmaceutical customers, with named application areas in antibody drug discovery, cell and gene therapy, and vaccine development, as well as vaccine developers building mRNA candidates. Its value proposition is built on speed and control: the platform is positioned to reduce time to results by up to 90% versus traditional outsourcing and enable a 3-day sequence-to-result mRNA workflow, while retaining intellectual property and build timeline control on the customer side. Membership in the International Gene Synthesis Consortium signals compliance with biosecurity best practices relevant to gene synthesis procurement.

Telesis Bio monetizes through three streams: sale of BioXp hardware systems, recurring revenue from BioXp consumable kits tied to the installed base, and enterprise licensing of the Gibson SOLA technology. Distribution combines direct enterprise field sales, a self-service customer portal for consumables, OEM-style licensing to biopharma partners (notably Regeneron, signed May 2025), and a global distributor network. The company has historically supplemented organic growth with M&A, including the November 2021 acquisition of Eton Bioscience for $13 million, and a $25 million financing round in September 2019 led by Northpond Ventures.

Codex DNA firmographics

Firmographics
Name
Codex DNA
Legal name
Telesis Bio Inc.
Website
https://codexdna.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Codex DNA, operating as Telesis Bio, is a publicly traded synthetic biology company that sells automated BioXp DNA/mRNA synthesis systems, proprietary reagent kits, and Gibson SOLA enzyme-based DNA assembly technology to biotechnology and pharmaceutical customers for therapeutic discovery workflows.
Ownership category
akta.pro rank

Codex DNA industry classification

Industry
Product category
Automated Synthetic Biology Instrumentation
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Synthetic biology automation
  • DNA synthesis systems
  • MRNA synthesis kits
  • Gene assembly technology
  • Biomolecule synthesis platforms

Where Codex DNA is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Codex DNA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. BioXp Systems (Hardware): Sale of automated BioXp synthesis systems including BioXp 3250 and BioXp 9600 platforms for on-site biomolecule synthesis.
  2. BioXp Kits (Consumables): Recurring sales of proprietary reagent kits for mRNA synthesis, gene synthesis, DNA cloning, DNA amplification, and NGS library preparation. Consumable revenue from repeat orders.
  3. Gibson SOLA Licensing: Technology licensing agreements allowing partners to deploy Gibson SOLA technology for internal rapid DNA and gene synthesis capabilities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise pricing for BioXp systems and consumables

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Codex DNA product offering

Product offering

Core offering

Codex DNA (Telesis Bio) sells automated benchtop synthesis systems—the BioXp 3250 and 9600 platforms—alongside proprietary BioXp reagent kits for on-site DNA, mRNA, gene synthesis, DNA cloning, amplification, libraries, and NGS library preparation. It also licenses its Gibson SOLA enzymatic DNA assembly technology to biopharma enterprises for internal deployment. The offering enables biotechnology and pharmaceutical researchers to perform rapid, on-demand synthesis of biomolecules, reducing reliance on external CROs/outsourcing for therapeutic discovery workflows.

Product overview

Telesis Bio (formerly operating as Codex DNA) offers a platform-plus-modules architecture centered on two core product lines: the BioXp Platform and the Gibson SOLA Platform. The BioXp Platform consists of automated synthesis systems (BioXp 3250 System and BioXp 9600 system) that work with a suite of BioXp Kits for mRNA synthesis, gene synthesis, DNA cloning, DNA amplification, libraries, and NGS library preparation. The Gibson SOLA Platform provides rapid on-site DNA and gene synthesis capabilities for integration with standard lab automation. Both platforms are supported by the myBioXperience secure ordering portal. The company focuses on therapeutic discovery applications including antibody drug discovery, cell and gene therapy, and vaccine development, enabling researchers to reduce time to results by up to 90% compared to traditional outsourcing methods.

Differentiator

Problem solved

Functional benefit

Brands

  • BioXp Platform: Automated platform for synthesis of DNA, mRNA, and other biomolecules
  • Gibson SOLA
  • myBioXperience

Products and services

  • BioXp 3250 System A benchtop automated synthesis system within the BioXp platform for DNA and mRNA production, designed for biotech and pharmaceutical researchers who need rapid, on-site synthesis of biomolecules for therapeutic discovery.
  • BioXp 9600 System A higher-throughput automated synthesis system within the BioXp platform for larger-scale DNA and mRNA production, targeting enterprise biotech and pharmaceutical customers with greater volume requirements for therapeutic discovery workflows.
  • BioXp Kits Proprietary consumable reagent kits designed for use on BioXp systems, covering mRNA synthesis, gene synthesis, DNA cloning, DNA amplification, library creation, and NGS library preparation. Sold as a recurring consumable line to researchers running BioXp workflows.
  • Gibson SOLA Platform Enzyme-based DNA assembly technology that enables rapid, high-fidelity on-site gene synthesis and cloning, designed to integrate with standard lab automation. Licensed to biopharma enterprises such as Regeneron to provide internal rapid DNA and gene synthesis capabilities for therapeutic discovery.

Quantifiable outcome

  • Up to 90% time reduction compared to traditional outsourcing methods
  • +2 more outcomes

Companies that use Codex DNA

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Codex DNA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Codex DNA partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • RegeneroncoreOEM/ Whitelabel/ Licensing Partner · 28 May 2025Regeneron has licensed the Gibson SOLA platform to enable rapid on-site DNA and gene synthesis capabilities for powering their therapeutic discovery pipeline. This licensing agreement represents a flagship enterprise customer adoption of the technology for internal deployment.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Codex DNA competitors and assessment

Company assessment

Direct peers

  • Twist Bioscience: Directly competes with Telesis Bio in synthetic DNA and gene synthesis, serving biotech and pharma with high-throughput synthesis platforms and oligo products. Highly overlapping customer base in antibody discovery and therapeutic R&D.
  • DNA Script: Competes in enzymatic on-site DNA synthesis with the SYNTAX benchtop platform, directly addressing the same 'on-site, IP-controlled synthesis' pain point that Gibson SOLA targets.
  • Synthego: Provides synthetic biology tools including engineered cells and gene synthesis services to therapeutic developers, overlapping with Telesis Bio's customer segments in cell/gene therapy and drug discovery.

Broad incumbents

  • GenScript: Large incumbent offering gene synthesis services and products to biotech and pharma customers. Overlaps with Telesis Bio's gene synthesis and mRNA workflow offerings, though primarily via outsourced service model.
  • Integrated DNA Technologies (IDT): Danaher-owned leader in oligonucleotide and gene synthesis, serving the same biotech/pharma customer base with synthetic nucleic acid products. Represents an entrenched incumbent in molecular biology consumables.
  • Eurofins Genomics: Major provider of outsourced gene synthesis and molecular biology services globally. Competes for the same biotech/pharma workflow budgets that Telesis Bio aims to internalize via the BioXp platform.
  • Thermo Fisher Scientific: Diversified life sciences tools giant offering instruments, reagents, and services across molecular biology and synthetic biology. Competes indirectly via broader portfolio including gene synthesis and nucleic acid workflow tools.
  • Agilent Technologies: Major analytical instrument and genomics consumables provider. Overlaps with Telesis Bio in molecular biology instrumentation and oligo/NGS consumables serving biotech and pharma R&D.

Emerging players

  • Molecular Assemblies: Pioneer in enzymatic DNA synthesis with a benchtop synthesis platform aimed at displacing outsourced gene synthesis. Direct technology competitor to Gibson SOLA's enzymatic synthesis approach.
  • ATUM (now part of Inspirevet): Synthetic biology tools company offering gene synthesis and protein engineering services, with overlapping customer base in antibody discovery and therapeutic protein development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Codex DNA social profiles

Digital presence

Codex DNA compliance and trust

Trust signal

Compliance1 record

Codex DNA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Codex DNA leadership team

Management profile

Number of profiles

Profiles10 records

Codex DNA funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Codex DNA M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Codex DNA

What does Codex DNA do?

Codex DNA (Telesis Bio) sells automated benchtop synthesis systems—the BioXp 3250 and 9600 platforms—alongside proprietary BioXp reagent kits for on-site DNA, mRNA, gene synthesis, DNA cloning, amplification, libraries, and NGS library preparation. It also licenses its Gibson SOLA enzymatic DNA assembly technology to biopharma enterprises for internal deployment. The offering enables biotechnology and pharmaceutical researchers to perform rapid, on-demand synthesis of biomolecules, reducing reliance on external CROs/outsourcing for therapeutic discovery workflows.

Is Codex DNA a public or private company?

Codex DNA is a private company. It is classified as public and is currently operating.

When was Codex DNA founded?

Codex DNA was founded in 2018. It employs 101 to 250 people.

Where is Codex DNA based?

Codex DNA is headquartered in San Diego, United States, in the North America region.

How does Codex DNA make money?

Three revenue lines are on record. BioXp Systems (Hardware) is the primary driver. The others are bioXp Kits (Consumables) and gibson SOLA Licensing.

Who are Codex DNA's main competitors?

Direct peers on record are Twist Bioscience, DNA Script and Synthego. Broad incumbents are GenScript, Integrated DNA Technologies (IDT), Eurofins Genomics, Thermo Fisher Scientific and Agilent Technologies. Emerging players are Molecular Assemblies and ATUM (now part of Inspirevet).

Does Codex DNA have an API?

No public API is recorded for Codex DNA.

What industry is Codex DNA in?

Codex DNA's product category is Automated Synthetic Biology Instrumentation. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCodex DNA Debuts Next-Generation Automated Synthetic Biology WorkstationBioXp™ 9600 systemCodex DNA announced commercial release and first shipment of the BioXp 9600 system, a next-generation automated synthetic biology workstation. The system automates overnight synthesis of genes, clones, DNA libraries, and mRNA, and will release additional kits in Q1 2023 to start from customer-provided linear or plasmid DNA.San Diego Business JournalCodex DNA Releases Synthetic Genome for OmicronCodex DNA released a full-length synthetic genome of the SARS-CoV-2 Omicron variant, built with its BioXp 3250 system. The genome enables researchers to produce virus for testing diagnostics, antibody treatments, therapies, and vaccines. The company also offers 14 SARS-CoV-2 synthetic genomes and custom services.GlobeNewswireCodex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and DevelopmentCodex DNA and Pfizer signed a multiyear early access collaboration and licensing agreement to develop Codex DNA's enzymatic DNA synthesis technology for Pfizer's mRNA vaccine and biopharma R&D. The deal includes an upfront payment and success-based technical milestones that could exceed $100 million, with additional payments tied to development, regulatory, and commercialization goals.PR NewswireThinking about buying stock in Kiora Pharmaceuticals, Tencent Music Entertainment, Naked Brand, Flotek Industries, or Codex DNA?InvestorsObserver issued critical PriceWatch Alerts for the stocks of Kiora Pharmaceuticals, Tencent Music Entertainment, Naked Brand Group, Flotek Industries, and Codex DNA on December 31, 2021. The alerts utilize a proprietary scoring system that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability. This announcement serves as a promotional disclosure for InvestorsObserver's analytical tools.BioSpaceCodex DNA Finishes 2021 Strong with Promising Pfizer PartnershipCodex DNA and Pfizer announced a partnership to improve the BioXP gene synthesis platform, with Pfizer paying $8 million upfront and eligible for up to $240 million in milestones. Codex will own the improved platform, while Pfizer owns R&D materials and commercial rights. The deal follows Codex's $13 million acquisition of Eton Bioscience.PR NewswireThinking about buying stock in Insignia Systems, Codex DNA, Energy Focus, Himax Technologies, or TRACON Pharmaceuticals?InvestorsObserver issued critical PriceWatch Alerts for stocks including Insignia Systems, Codex DNA, Energy Focus, Himax Technologies, and TRACON Pharmaceuticals. The alerts are generated using a proprietary scoring methodology that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability. This announcement serves as a promotional disclosure for InvestorsObserver's stock analysis tools.San Diego Business JournalCodex DNA Acquires Eton Biosciences for $13MCodex DNA acquired Eton Biosciences for $13 million, announced Nov. 9, to expand its synthetic biology offerings. The deal is expected to be slightly dilutive to earnings per share in 2022 and accretive thereafter. Codex DNA shares fell about 4% the day after the announcement.Technology NetworksTargeted Libraries and Their Applications for Directed Evolution of EnzymesCellibre, a cellular agriculture company, partnered with Codex DNA to accelerate enzyme engineering for cannabinoid production using targeted library approaches. The collaboration utilized Codex DNA's BioXp™ system to significantly speed up Design.Build.Test cycles and enable rapid iteration of enzyme candidates.YahooThese 3 Stocks May Be Reaching a Bottom; Analysts Say ‘Buy’Analysts rate UpHealth, Femasys, and Codex DNA as buy opportunities, citing low share prices and high upside. UpHealth shares fell 41% since SPAC merger, Femasys 47%, and Codex DNA 33%. Analysts set price targets of $13, $25, and $23, implying 131%, 262%, and 55% upside respectively.BioWorldCodex DNA takes vaccine printing from concept to realityCodex DNA Inc. claims to have a fully automated, tabletop vaccine printer ready for market in 18-24 months. The technology could help health officials respond to future pandemics or produce faster influenza vaccines.